On September 5, 2025 Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection, reported an oral presentation in partnership with University Health Network’s (UHN) Princess Margaret Cancer Centre at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer on September 6-9, 2025, in Barcelona, Spain (Press release, Foresight Diagnostics, SEP 5, 2025, View Source [SID1234655792]). The presentation will feature analysis of MRD performance in a cohort of stage I lung cancer patients from the ctDNA-Lung DETECT study using Foresight CLARITY, the company’s ultrasensitive circulating tumor DNA (ctDNA) assay with a reported detection limit of less than one part per million.1
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Foresight CLARITY demonstrated high ctDNA-MRD detection rates at both pre- and post-operative timepoints. Highlights include:
Pre-operative MRD detection was 68% and post-operative MRD detection was 38%.
Clinical sensitivity for relapse detection at post-surgical landmark was 55%, with a median lead time of 10 months prior to clinical recurrence.
Post-operative MRD detection was significantly associated with worse recurrence-free survival (RFS) at both post-operative landmark (HR = 3.14, p = 0.0425) and at the one-year timepoint (HR = 8.20, p = 0.0001).
"The field has historically recognized the challenges of using ctDNA-MRD assays in early-stage lung cancer, particularly due to the low-shedding nature of these tumors. However, based on the results of our study, ultrasensitive assays can offer actionable insights and may help us achieve personalized treatment strategies, such as adjuvant therapy escalation in high-risk patients," said Dr. Natasha Leighl, Division Head, Medical Oncology and Hematology, UHN’s Princess Margaret Cancer Centre, Toronto.
"Detecting MRD in early-stage lung cancer patients before or after surgery may open new clinical applications not possible with current tools," said David Kurtz, Md, PhD, Chief Medical Officer and Head of Research at Foresight Diagnostics. "We look forward to continuing to support innovative studies that advance precision medicine for lung cancer."
Presentation Details:
Ultrasensitive MRD improves detection in resectable stage I NSCLC
Presenter: Natasha Leighl, BSc, MMSc, MD (Division Head, Medical Oncology and Hematology, UHN’s Princess Margaret Cancer Centre, Toronto, Canada)
Date: Sunday, September 7th, 2025
Time: 3:15pm – 4:30pm CEST
Session: MA03. New Advances in Circulating Biomarkers
To meet with the Foresight Diagnostics team at IASLC 2025, please contact us here or email [email protected].